(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/068907 A3

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61K 39/145* (2006.01)
A61K 39/12 (2006.01)

(21) International Application Number:
PCT/GB2006/004634

(22) International Filing Date:
12 December 2006 (12.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0525321.6	13 December 2005 (13.12.2005)	GB
0609902.2	18 May 2006 (18.05.2006)	GB
0620336.8	12 October 2006 (12.10.2006)	GB
0620337.6	12 October 2006 (12.10.2006)	GB

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS SA** [BE/BE]; Rue De l'Institut 89, B-1330 Rixensart (BE).

(71) Applicant *(for MG only)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **VANDEPAPELIERE, Pierre** [FR/BE]; GlaxoSmithKline Biologicals sa, Rue De l'Institut 89, B-1330 Rixensart (BE).

(74) Agent: **CHIAPPINELLI, Susan, Ann**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
9 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VACCINE COMPOSITIONS COMPRISING A SAPONIN ADJUVANT

(57) Abstract: The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30μg. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 μg of a lipopolysaccharide and between 1 and 30 μg of an immunologically active saponin fraction presented in the form of a liposome.

WO 2007/068907 A3